Cornerstone (CRTX) Sells Product Rights of Factive Tablets, Spectracef Family to Merus Labs (MSLI), Vansen
Tweet
Share
E-mailGet Alerts CRTX Hot Sheet
Join SI Premium – FREE
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today announced the divestiture of certain product rights to Factive (gemifloxacin mesylate) tablets and the Spectracef (cefditoren pivoxil) family of products in a series of transactions with Merus Labs International Inc. (NASDAQ: MSLI) and Vansen Pharma Inc.
Under terms of the agreements, Cornerstone will receive an undisclosed amount of cash consideration for the product rights and inventory transferred and the acquirers will assume certain product related liabilities.
Under terms of the agreements, Cornerstone will receive an undisclosed amount of cash consideration for the product rights and inventory transferred and the acquirers will assume certain product related liabilities.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real and RE/MAX Holdings receive court approval for merger
- Boeing names Ryan Shedd as new SVP and controller
- Elroy Air wins $46M U.S. Army contract for cargo drone system
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
